Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR [Corrigendum]

Laidlaw TM, Menzies-Gow A, Caveney S, et al. J Asthma Allergy. 2023;16:915–932.

The authors have advised there is an error in Figure 1 on page 922. The n= x-axis data were transposed for the treatment groups for both the Patients with NPs and Patients without NPs. The correct Figure 1 is as follows.

Figure 1 AAER over 52 weeks in patients with or without nasal polyps in the 2 years before randomization in the NAVIGATOR study. Abbreviations: AAER, annualized asthma exacerbation rate; CI, confidence interval; NP, nasal polyp; Q4W, every 4 weeks. Note: n, number of patients contributing to the analysis.

The authors apologize for this error.

Read the original article

© 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.